ミロガバリンを新規に処方された患者に対する保険薬局における使用実態調査

Background:Peripheral neuropathic pain increases economic burden and reduces quality of life. Purpose:In this study, to conduct the preliminary verification that leads a specific method of medication instruction for peripheral neuropathic pain medicine“mirogabalin”, we investigated the medication status of patients who were newly prescribed mirogabalin by using the medical instruction record. Methods:From April 2019 to April 2020, we monitored pain score and side effects for 88 patients who newly taken mirogabalin up to 4 weeks. Results and Conclusion:30％ responders were 45.9％ and 50％ responders were 34.4％. The most common side effects were“somnolence”and“dizziness”which were more common in women than in men. There were 59 patients who actually felt the effect, of which 81.4％ and 94.9％ had the effect by 1st week and 2nd week, respectively. 38 patients felt side effects, of which 94.7％ had side effects within a few days. This fact‒finding survey of mirogabalin suggests its side effects appears earlier than effects. Every time of medication instruction by pharmacist, checking the expected onset of effect and the type of side effects is very useful to confirm patients’ medication status over time. As a future task, we will carry out a usage survey using common evaluation items with much number of pharmacies cooperation. Through this analysis, we aim to create the standardized medication instruction materials.